Depression treatment and short-term healthcare expenditures among elderly Medicare beneficiaries with chronic physical conditions

Journal of Negative Results in Biomedicine

Usha Sambamoorthi²  Patricia A Findley¹  Neel Shah²  Chan Shen³ 

[1] School of Social Work, Rutgers University, 536 George Street, New Brunswick, NJ 08901, USA;Department of Pharmaceutical Systems and Policy, School of Pharmacy, West Virginia University, PO Box 9510, Morgantown, WV 26506-9510, USA;Department of Biostatistics, Division of Quantitative Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

关键词: Expenditures;    Antidepressants;    Depression;    Chronic physical conditions;   

Others  :  812376
DOI  :  10.1186/1477-5751-12-15

 received in 2012-10-16, accepted in 2013-10-13,  发布年份 2013

【 摘 要 】

Background

Research on the impact of depression treatment on expenditures is nascent and shows results that vary from negative associations with healthcare expenditures to increased expenditures. However many of these studies did not include psychotherapy as part of the depression treatment. None of these studies included “no treatment” as a comparison group. In addition, no study has included a broad group of chronic physical conditions in studying depression treatment expenditures.

Objective

We determined the association between depression treatment and short-term healthcare expenditures using a nationally representative sample of Medicare beneficiaries with chronic physical conditions and depression.

Method

In this retrospective cohort study, we examined the association between depression treatment in the baseline year and healthcare expenditures in the following year using data from 2000 through 2005 of the Medicare Current Beneficiary Survey (MCBS), a nationally representative survey of Medicare beneficiaries. Using the rotating panel design of MCBS, we derived five two-year cohorts: 2000–2001, 2001–2002, 2002–2003, 2003–2004, and 2004–2005. The study sample included 1,055 elderly Medicare beneficiaries aged 65 or over. We compared healthcare expenditures of no depression treatment group with depression treatment groups using t-tests. Linear regressions of log-transformed dollars were used to assess the relationship between depression treatment and healthcare expenditures after controlling for demographic, socio-economic, health status, lifestyle risk factors, year of observation and baseline expenditures.

Results

Compared to no depression treatment ($16,795), the average total expenditures were higher for those who used antidepressants only ($17,425) and those who used psychotherapy with or without antidepressants ($19,733). After controlling for the independent variables, antidepressant use and psychotherapy with or without antidepressants were associated with 20.2% (95% CI: 14.1-26.7%) and 29.4% (95% CI: 18.8-41.0%) increase in total expenditures, respectively. We observed that depression treatment was positively associated with inpatient, medical provider and prescription drug expenditures.

Conclusion

Among the elderly Medicare beneficiaries with chronic physical conditions, depression treatment was associated with greater short-term healthcare expenditures. Future research needs to replicate these findings and also examine whether depression treatment reduces expenditures over a longer period of time.

【 授权许可】

   
2013 Shen et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Egede LE, Zheng D, Simpson K: Comorbid depression is associated with increased health care use and expenditures in individuals with diabetes. Diabetes Care 2002, 25:464-470.
• [2]Simon GE, Manning WG, Katzelnick DJ, Pearson SD, Henk HJ, Helstad CS: Cost-effectiveness of systematic depression treatment for high utilizers of general medical care. Arch Gen Psychiatry 2001, 58:181-187.
• [3]Simon GE, Katon WJ, Lin EH, Rutter C, Manning WG, Von Korff M, Ciechanowski P, Ludman EJ, Young BA: Cost-effectiveness of systematic depression treatment among people with diabetes mellitus. Arch Gen Psychiatry 2007, 64:65-72.
• [4]Tiwari A, Rajan M, Miller D, Pogach L, Olfson M, Sambamoorthi U: Guideline-consistent antidepressant treatment patterns among veterans with diabetes and major depressive disorder. Psychiatr Serv 2008, 59:1139-1147.
• [5]Katon WJ, Lin EH, Von Korff M, Ciechanowski P, Ludman EJ, Young B, Peterson D, Rutter CM, McGregor M, McCulloch D: Collaborative care for patients with depression and chronic illnesses. N Engl J Med 2010, 363:2611-2620.
• [6]Simon GE, Katon WJ, VonKorff M, Unützer J, Lin EH, Walker EA, Bush T, Rutter C, Ludman E: Cost-effectiveness of a collaborative care program for primary care patients with persistent depression. Am J Psychiatry 2001, 158:1638-1644.
• [7]Gilbody S, Bower P, Fletcher J, Richards D, Sutton AJ: Collaborative care for depression: a cumulative meta-analysis and review of longer-term outcomes. Arch Intern Med 2006, 166:2314-2321.
• [8]Nutting PA, Rost K, Smith J, Werner JJ, Elliot C: Competing demands from physical problems: effect on initiating and completing depression care over 6 months. Arch Fam Med 2000, 9:1059-1064.
• [9]Rost K, Nutting P, Smith J, Coyne JC, Cooper-Patrick L, Rubenstein L: The role of competing demands in the treatment provided primary care patients with major depression. Arch Fam Med 2000, 9:150-154.
• [10]Klinkman MS: Competing demands in psychosocial care. A model for the identification and treatment of depressive disorders in primary care. Gen Hosp Psychiatry 1997, 19:98-111.
• [11]Pan A, Sun Q, Okereke OI, Rexrode KM, Rubin RR, Lucas M, Willett WC, Manson JE, Hu FB: Use of antidepressant medication and risk of type 2 diabetes: results from three cohorts of US adults. Diabetologia 2011, 55:63-72.
• [12]Kivimäki M, Hamer M, Batty GD, Geddes JR, Tabak AG, Pentti J, Virtanen M, Vahtera J: Antidepressant medication use, weight gain, and risk of type 2 diabetes: a population-based study. Diabetes Care 2010, 33:2611-2616.
• [13]Glassman AH, O’Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT Jr, Krishnan KR, van Zyl LT, Swenson JR, Finkel MS, Landau C, Shapiro PA, Pepine CJ, Mardekian J, Harrison WM, Barton D, Mclvor M: Sertraline Antidepressant Heart Attack Randomized Trial (SADHEART) Group. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002, 288:701-709.
• [14]Joynt KE, O’Connor CM: Lessons from SADHART, ENRICHD, and other trials. Psychosom Med 2005, 67(Suppl 1):S63-S66.
• [15]Andersen RM: Revisiting the behavioral model and access to medical care: does it matter? J Health Soc Behav 1995, 36:1-10.
• [16]Rayner L, Price A, Evans A, Valsraj K, Higginson IJ, Hotopf M: Antidepressants for depression in physically ill people. Cochrane Database Syst Rev 2010., 17CD007503
• [17]Centers for Medicare and Medicaid Services: Medicare Current Beneficiary Survey (MCBS) related files. Available at: https://www.cms.gov/MCBS webcite. Accessed 07/20, 2011
• [18]2011 Quick Reference Guide (HEDIS/QARR MEASURES). Available at: http://www.healthfirstny.org/pdf/Provider-Materials/Provider-Quick-Reference-Guide-HEDIS-QARR-Measures-2011_NY.pdf webcite. Accessed 07/07, 2011
• [19]Wei W, Sambamoorthi U, Olfson M, Walkup JT, Crystal S: Use of psychotherapy for depression in older adults. Am J Psychiatry 2005, 162:711-717.
• [20]Crystal S, Sambamoorthi U, Walkup JT, Akincigil A: Diagnosis and treatment of depression in the elderly medicare population: predictors, disparities, and trends. J Am Geriatr Soc 2003, 51:1718-1728.
• [21]Sambamoorthi U, Olfson M, Walkup JT, Crystal S: Diffusion of new generation antidepressant treatment among elderly diagnosed with depression. Med Care 2003, 41:180-194.
• [22]Sambamoorthi U, Shen C, Findley P, Frayne S, Banerjea R, Sambamoorthi U, Shen C, Findley P, Frayne S, Banerjea R: Depression treatment patterns among women veterans with cardiovascular conditions or diabetes. World Psychiatry 2010, 9:177-182.
• [23]Bureau of Labor Statistics: Consumer Price Index Detailed Report Tables. Available at: http://www.bls.gov/cpi/cpid05av.pdf webcite. Accessed 07/20, 2011
• [24]Centers for Disease Control and Prevention (CDC): BMI Classification [online]. Available at: http://www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/index.html webcite. Accessed 10/03, 2011
• [25]Monheit AC: Persistence in health expenditures in the short run: prevalence and consequences. Med Care 2003, 4(7 Suppl):III53-III64.
• [26]Halvorsen R, Palmquist R: The interpretation of dummy variables in Semilogarithmic equations. Am Econ Rev 1980, 70:474-475.
• [27]Findley P, Shen C, Sambamoorthi U: Multimorbidity and persistent depression among veterans with diabetes, heart disease, and hypertension. Health Soc Work 2011, 36:109-119.
• [28]Masand P, Narasimhan M: Major depressive disorder and medical illness: STAR*D outcomes. Curr Psychiatry Rep 2006, 8:165-166.
• [29]Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M: Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006, 163:1905-1917.
• [30]Thompson D, Buesching D, Gregor KJ, et al.: Patterns of antidepressant use and their relation to costs of care. Am J Manag Care 1996, 2:1239-1246.
• [31]Katon W, Cantrell CR, Sokol MC, Chiao E, Gdovin JM: Impact of antidepressant drug adherence on comorbid medication use and resource utilization. Arch Intern Med 2005, 165(21):2497-2503.
• [32]Yates WR, Mitchell J, Rush AJ, Trivedi MH, Wisniewski SR, Warden D, Hauger RB, Fava M, Gaynes BN, Husain MM, Bryan C: Clinical features of depressed outpatients with and without co-occurring general medical conditions in STAR*D. Gen Hosp Psychiatry 2004, 26:421-429.
• [33]Charbonneau A, Rosen AK, Owen RR, Spiro A 3rd, Ash AS, Miller DR, Kazis L, Kader B, Cunningham F, Berlowitz DR: Monitoring depression care: in search of an accurate quality indicator. Med Care 2004, 42:522-531.